


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED

東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2348)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 30 DECEMBER 2019

Reference is made to the circular (the “Circular”) of Dawnrays Pharmaceutical (Holdings) Ltd. (the “Company”) dated 21 November 2019 and the notice (the “Notice”) of the extraordinary general meeting (the “EGM”) of even date. Unless otherwise defined, capitalized terms used herein shall have the same meanings as defined in the Circular.

POLL RESULTS OF THE EGM

At the EGM held on 30 December 2019, voting of the proposed ordinary resolution as set out in the Notice was taken by way of poll. The Company’s Hong Kong branch share registrar and transfer office, Tricor Abacus Limited, acted as the scrutineer for the vote-taking at the EGM.

As at the date of the EGM, the total number of Shares in issue was 1,556,581,000 Shares.

Pursuant to the note to Rule 17.03(4) of the Rules Governing the Listing of Securities on the Stock Exchange (the “Listing Rules”), Mr. Chen Shaojun and his associates are required to abstain, and have abstained, from voting on the resolution. As at the date of the EGM, Mr. Chen Shaojun held an aggregate of 8,377,000 shares and 16,000,000 share options of the Company. Accordingly, the total number of shares entitling the holders to attend and vote for or against the resolution proposed at the EGM was 1,548,204,000 shares.

Save as disclosed above, there were no shares the holder of which is required under the Listing Rules to abstain from voting on the proposed resolution at the EGM. There were no shares entitling the holder to attend and abstain from voting in favour of the proposed resolution at the EGM as set out in Rule 13.40 of the Listing Rules. No parties have stated their intention in the Circular to vote against the resolution proposed at the EGM or to abstain from voting.

**for identification purpose only*

The Board is pleased to announce that the proposed ordinary resolution as set out in the Notice was duly passed by the Shareholders by way of poll at the EGM. Details of the proposed ordinary resolution were set out in the Notice and the poll results for the ordinary resolution is as follows:

Ordinary Resolution		Number of Votes (%)	
		For	Against
1.	To approve, confirm and ratify the grant of 64,000,000 share options of the Company (the “ Options ”) to Mr. Chen Shaojun, the executive director and the chief executive officer of the Company, to subscribe for 64,000,000 shares of the Company (the “ Shares ”) at the exercise price of HK\$1.38 per Share and on the terms and conditions as set out in the Circular and authorise any one director of the Company to do all such acts and/or execute all such documents as may be necessary or expedient in order to give full effect to such grant and exercise of the Options.	964,149,067 (89.08%)	118,170,095 (10.92%)

As more than 50% of the votes attaching to the Shares held by the Shareholders present and voting in person or by proxy at the EGM were cast in favour of above ordinary resolution numbered 1, the above resolution was duly passed as an ordinary resolution of the Company.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Ltd.
Li Kei Ling
Chairman

Hong Kong, 30 December 2019

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Chen Shaojun; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.